Bank Pictet & Cie Europe AG Sells 75,650 Shares of Danaher Co. (NYSE:DHR)

Bank Pictet & Cie Europe AG lessened its stake in Danaher Co. (NYSE:DHR) by 32.5% during the third quarter, HoldingsChannel reports. The firm owned 157,001 shares of the conglomerate’s stock after selling 75,650 shares during the period. Danaher comprises approximately 1.0% of Bank Pictet & Cie Europe AG’s portfolio, making the stock its 26th biggest holding. Bank Pictet & Cie Europe AG’s holdings in Danaher were worth $43,649,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of DHR. Benjamin Edwards Inc. grew its holdings in Danaher by 1.8% during the 2nd quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock valued at $538,000 after buying an additional 38 shares in the last quarter. Wedge Capital Management L L P NC boosted its position in shares of Danaher by 3.2% in the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after acquiring an additional 38 shares during the period. Patrick M Sweeney & Associates Inc. grew its stake in Danaher by 3.4% during the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock valued at $307,000 after acquiring an additional 40 shares in the last quarter. Trust Co of Kansas increased its holdings in Danaher by 4.1% during the 2nd quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock worth $255,000 after acquiring an additional 40 shares during the period. Finally, Abacus Planning Group Inc. lifted its stake in Danaher by 0.7% in the 2nd quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock worth $1,359,000 after purchasing an additional 40 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is currently owned by company insiders.

Danaher Stock Down 4.0 %

DHR opened at $261.28 on Wednesday. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $281.70. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The business’s 50-day moving average price is $270.67 and its 200-day moving average price is $260.46. The company has a market cap of $193.53 billion, a P/E ratio of 44.28, a P/E/G ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period in the previous year, the firm earned $2.02 EPS. On average, equities analysts expect that Danaher Co. will post 7.59 EPS for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.41%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Wells Fargo & Company began coverage on shares of Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target for the company. Barclays decreased their target price on Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research note on Wednesday. The Goldman Sachs Group lifted their price target on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Evercore ISI upped their price objective on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $300.00 target price on shares of Danaher in a research report on Friday, September 6th. Seven equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $281.47.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.